Keywords
Last Name
Institution

David Vorchheimer

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentCardiology
Address5 East 98th Street
3rd Floor
New York NY 10029
Phone212-241-4258
Fax212-360-7190

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost. 2013 Jan; 11(1):100-6.
      View in: PubMed
    2. Davidson KW, Burg MM, Kronish IM, Shimbo D, Dettenborn L, Mehran R, Vorchheimer D, Clemow L, Schwartz JE, Lespérance F, Rieckmann N. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry. 2010 May; 67(5):480-8.
      View in: PubMed
    3. Lookstein RA, Talenfeld AD, Raju R, Vorchheimer DA, Olin JW, Marin ML. Sirolimus-eluting stent placement for refractory renal artery in-stent restenosis: sustained patency and clinical benefit at 24 months. Vasc Med. 2009 Nov; 14(4):361-4.
      View in: PubMed
    4. Zafar MU, Ibáñez B, Choi BG, Vorchheimer DA, Piñero A, Jin X, Sharma RK, Badimon JJ. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan; 103(1):205-12.
      View in: PubMed
    5. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):776S-814S.
      View in: PubMed
    6. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Jun 3; 117(22):2865-74.
      View in: PubMed
    7. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007 Oct; 98(4):883-8.
      View in: PubMed
    8. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007 Jan; 5(1):82-90.
      View in: PubMed
    9. Rieckmann N, Kronish IM, Haas D, Gerin W, Chaplin WF, Burg MM, Vorchheimer D, Davidson KW. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006 Nov; 152(5):922-7.
      View in: PubMed
    10. Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, Davidson KW. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006 Nov; 21(11):1178-83.
      View in: PubMed
    11. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc. 2006 Jan; 81(1):59-68.
      View in: PubMed
    12. Vorchheimer DA. What is QT interval prolongation? J Fam Pract. 2005 Jun; Suppl:S4-7.
      View in: PubMed
    13. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):513S-548S.
      View in: PubMed
    14. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis. 2004 Feb; 17(1):51-61.
      View in: PubMed
    15. Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, Fallon JT, Fuster V, Badimon JJ. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation. 2003 Apr 1; 107(12):1658-63.
      View in: PubMed
    16. Vorchheimer DA, Fuster V. Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug; 23(15):1142-4.
      View in: PubMed
    17. Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. JAMA. 2001 Nov 7; 286(17):2154-6.
      View in: PubMed
    18. Harnick DJ, Vorchheimer DA. Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory? Curr Cardiol Rep. 2001 Sep; 3(5):355-61.
      View in: PubMed
    19. Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, Lincoff AM, Labinaz M, Joseph DM, McDougal MF, Kleiman NS. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001 Jul 24; 104(4):399-405.
      View in: PubMed
    20. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000 Nov; 153(1):181-9.
      View in: PubMed
    21. Vorchheimer DA. Current state of thrombolytic therapy. Curr Cardiol Rep. 1999 Sep; 1(3):212-20.
      View in: PubMed
    22. Nelson JE, Croft LB, Nahar T, Vorchheimer D. Evaluation of subclavian catheter position. J Cardiothorac Vasc Anesth. 1999 Jun; 13(3):359-61.
      View in: PubMed
    23. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999 Apr 21; 281(15):1407-14.
      View in: PubMed
    24. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation. 1998 Feb 3; 97(4):312-4.
      View in: PubMed
    25. Fuster V, Vorchheimer DA. Prevention of atherosclerosis in coronary-artery bypass grafts. N Engl J Med. 1997 Jan 16; 336(3):212-3.
      View in: PubMed
    Vorchheimer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067